No insider purchase over the last 90 days. The latest, by 이상수, was filed 09 Jun 2026.
Kolmar BioTech, Inc.: what insiders have been doing
Kolmar BioTech, Inc., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to DART (FSS). In the past year (1 November 2025 to 1 November 2026), 9 filings came from 6 insiders.
On the market, 3 insiders bought (4 purchases totalling €12k) while 1 insider sold (1 sale). The totals do not cover 4 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The buyers include 2 senior executives. One trade stands out by size: a purchase of €12k from 이상수, disclosed on 4 June 2026, or 0.056% of market capitalisation.
The clock since the last published purchase (9 June 2026) now reads 153 days. The median gap between a trade and its publication by DART (FSS) is 7 days. The shorter that gap, the sooner other investors can see what insiders have done.
With 9 filings in twelve months, the company is more active than the median of 7 filings across the 2,655 companies we follow on the same exchange. Our records for Kolmar BioTech, Inc. go back to 2021, with 21 purchases and 40 sales on the open market in total.
In the same sector, recent insider purchases at Dynavox Group AB and UCB also feature in our signals. This summary is built from DART (FSS) disclosures alone and does not predict where the share price will go.
Who traded when
BuySale+2 other insiders
Since the insiders bought
- -16.9%Entry ₩2,460 · Close 30 Oct 2026 ₩2,045
- -18.5%Entry ₩2,510 · Close 30 Oct 2026 ₩2,045
- -36.5%Entry ₩2,560 · Close at T+365 ₩1,626
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
- ●Executives0DART
- 4,814 sharesShareKRXDART:20260609000365Canonical exit: 7 Sept 2026 (T+90)
- 5,000 sharesShareKRXDART:20260604000402Canonical exit: 2 Sept 2026 (T+90)
- 8,247 shares@ ₩2,639.53290.056% mcap100.0% of flowShareKRXDART:20260604000295Canonical exit: 27 Aug 2026 (T+90)
- 0KRXDART:20260403001322
- 20,636,658 sharesKRXDART:20260403001287Canonical exit: 1 Jun 2026 (T+90)
- ●Executives0DART
- 162,336 sharesKRXDART:20260310003085
- 0KRXDART:20260310002955
- 2,117,011 sharesShareKRXDART:20250828000406Canonical exit: 26 Nov 2025 (T+90)
- 2,142,110 sharesShareKRXDART:20250828000410Canonical exit: 26 Nov 2025 (T+90)
- 5,657,027 sharesKRXDART:20250828000383
- 5,657,027 sharesKRXDART:20250828000402Canonical exit: 25 Nov 2025 (T+90)
- 950,000 sharesKRXDART:20241213000293Canonical exit: 6 Mar 2025 (T+90)
- 449,221 sharesKRXDART:20240906000470
- ShareKRXDART:20240820000045Canonical exit: 12 Nov 2024 (T+90)
- ShareKRXDART:20240812000264Canonical exit: 6 Nov 2024 (T+90)
- ShareKRXDART:20240807000453Canonical exit: 31 Oct 2024 (T+90)
- ShareKRXDART:20240805000412Canonical exit: 27 Oct 2024 (T+90)
- 72,336 sharesKRXDART:20240805000295
- ShareKRXDART:20240729000248Canonical exit: 20 Oct 2024 (T+90)
- ShareKRXDART:20240729000238
- ShareKRXDART:20240729000257Canonical exit: 23 Oct 2024 (T+90)
- ShareKRXDART:20240724000354Canonical exit: 16 Oct 2024 (T+90)
- ShareKRXDART:20240718000068Canonical exit: 10 Oct 2024 (T+90)
25 of 75 declarations
About Kolmar BioTech, Inc.
우정바이오 is a healthcare and pharmaceutical company listed on the XKRX market. It specializes in the development of biopharmaceutical products.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
